|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
|
The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced. |
|||||||||||||||||||||||||||||||||||||||||||||||||
Download
|
|
NirFP | Xho I | Hind III | Pst I | Kpn I | Apa I | BamH I | STOP | ||||||||||||||||||||||||
BspE I | Bgl II | Sac I | EcoR I | Sal I | Sac II | Sma I/Xma I | Xba I# | ||||||||||||||||||||||||
... | TCC.GGA | .CTC | . | AGA.T | CT | .C | GA.G | CT.C | AA.GCT.T | C | G.AAT.T | C | T.GCA. | G | TC.GAC | . | GGT.A | CC | .GC | G.G | G | C.CC | G. | GG | A.TCC | .ACC.GGA | . | TC | T.AG | A | .... |
# – sites are blocked by dam methylation. If you wish to digest the vector with these enzymes, you will need to transform the vector into a dam- host and make fresh DNA.
pNirFP-C is a mammalian expression vector encoding near-infrared fluorescent protein NirFP (see reporter description). The vector allows generation of fusions to the NirFP C-terminus and expression of NirFP fusions or NirFP alone in eukaryotic (mammalian) cells.
NirFP codon usage is optimized for high expression in mammalian cells (humanized) [Haas et al., 1996]. To increase mRNA translation efficiency, Kozak consensus translation initiation site is generated upstream of the NirFP coding sequence [Kozak, 1987]. Multiple cloning site (MCS) is located between NirFP coding sequence and SV40 polyadenylation signal (SV40 polyA).
The vector backbone contains immediate early promoter of cytomegalovirus (PCMV IE) for protein expression, SV40 origin for replication in mammalian cells expressing SV40 T-antigen, pUC origin of replication for propagation in
SV40 early promoter (PSV40) provides neomycin resistance gene (Neor) expression to select stably transfected eukaryotic cells using G418. Bacterial promoter (P) provides kanamycin resistance gene expression (Kanr) in
Generation of NirFP fusion proteins
A localization signal or a gene of interest can be cloned into MCS of the vector. It will be expressed as a fusion to the NirFP C-terminus when inserted in the same reading frame as NirFP and no in-frame stop codons are present. NirFP-tagged fusions retain fluorescent properties of the native protein allowing fusion localization in vivo. Unmodified vector will express NirFP when transfected into eukaryotic (mammalian) cells.
Note: The plasmid DNA was isolated from dam+-methylated
Expression in mammalian cells
pNirFP-C vector can be transfected into mammalian cells by any known transfection method. CMV promoter provides strong, constitutive expression of NirFP or its fusions in eukaryotic cells. If required, stable transformants can be selected using G418 [Gorman, 1985].
Propagation in
Suitable host strains for propagation in
Location of features
PCMV IE: 1-589
Enhancer region: 59-465
TATA box: 554-560
Transcription start point: 583
NirFP
Kozak consensus translation initiation site: 606-616
Start codon (ATG): 613-615
Stop codon: 1393-1395
Last amino acid in mKate2: 1312-1314
MCS: 1315-1392
SV40 early mRNA polyadenylation signal
Polyadenylation signals: 1535-1540 & 1564-1569
mRNA 3' ends: 1573 & 1585
f1 single-strand DNA origin: 1632-2087
Bacterial promoter for expression of Kanr gene
-35 region: 2149-2154
-10 region: 2172-2177
Transcription start point: 2184
SV40 origin of replication: 2428-2563
SV40 early promoter
Enhancer (72-bp tandem repeats): 2261-2332 & 2333-2404
21-bp repeats: 2408-2428, 2429-2449 & 2451-2471
Early promoter element: 2484-2490
Major transcription start points: 2480, 2518, 2524 & 2529
Kanamycin/neomycin resistance gene
Neomycin phosphotransferase coding sequences:
Start codon (ATG): 2612-2614
Stop codon: 3404-3406
G->A mutation to remove Pst I site: 2794
C->A (Arg to Ser) mutation to remove BssH II site: 3140
Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal
Polyadenylation signals: 3642-3647 & 3655-3660
pUC plasmid replication origin: 3991-4634
NirFP-related materials (also referred to as "Products") are intended for research use only. The Products are covered by U.S. Pat. 7,972,834; 8,138,320; European Pat. 1994149; and other Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License.
Copyright 2002-2023 Evrogen. All rights reserved. Evrogen JSC, 16/10 Miklukho-Maklaya str., Moscow, Russia, Tel +7(495)988-4084, Fax +7(495)988-4085, e-mail:evrogen@evrogen.com |